Page last updated: 2024-10-24

negative regulation of glucocorticoid biosynthetic process

Definition

Target type: biologicalprocess

Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucocorticoids. [GOC:mah]

Negative regulation of glucocorticoid biosynthetic process is a complex and multifaceted process involving multiple regulatory mechanisms that control the production of glucocorticoid hormones. Glucocorticoids, such as cortisol in humans, are crucial for maintaining homeostasis and regulating a wide range of physiological processes, including stress response, metabolism, and immune function. Excessive production of glucocorticoids can lead to various health issues, including Cushing's syndrome, while insufficient production can result in adrenal insufficiency. Therefore, tightly controlling the biosynthesis of these hormones is essential for maintaining health.

The biosynthesis of glucocorticoids occurs primarily in the adrenal cortex, specifically in the zona fasciculata. The process involves a series of enzymatic steps, starting with cholesterol and ultimately leading to the production of cortisol. The key enzymes involved in this pathway include cholesterol side-chain cleavage enzyme (CYP11A1), 21-hydroxylase (CYP21A2), 11β-hydroxylase (CYP11B1), and 17α-hydroxylase (CYP17A1).

Negative regulation of glucocorticoid biosynthesis aims to prevent excessive production of these hormones, maintaining their levels within a healthy range. This regulation occurs at multiple levels, including:

1. **Hypothalamic-Pituitary-Adrenal (HPA) Axis:** This axis plays a central role in regulating glucocorticoid production. The hypothalamus releases corticotropin-releasing hormone (CRH), which stimulates the anterior pituitary gland to release adrenocorticotropic hormone (ACTH). ACTH then acts on the adrenal cortex, promoting the biosynthesis of glucocorticoids. However, high levels of glucocorticoids feedback negatively on both the hypothalamus and pituitary, reducing the release of CRH and ACTH, thus limiting further glucocorticoid production.

2. **Direct Regulation at the Adrenal Cortex:** Various factors can directly influence glucocorticoid biosynthesis within the adrenal cortex. These include:
- **Cytokine signaling:** Pro-inflammatory cytokines like IL-1, IL-6, and TNF-α can stimulate glucocorticoid production, while anti-inflammatory cytokines like IL-10 can suppress it.
- **Stress response:** Acute stress triggers the HPA axis, leading to increased glucocorticoid production. However, prolonged stress can lead to chronic hypercortisolism, which can have detrimental effects on health.
- **Circadian rhythm:** Glucocorticoid production follows a diurnal rhythm, with peak levels occurring in the morning and lowest levels in the evening. This rhythm is regulated by the circadian clock in the hypothalamus.

3. **Enzyme Inhibition:** Certain factors can directly inhibit the activity of enzymes involved in glucocorticoid biosynthesis. For example:
- **Metopirone:** This drug inhibits 11β-hydroxylase, preventing the conversion of 11-deoxycortisol to cortisol.
- **Ketoconazole:** This antifungal drug can also inhibit CYP11A1 and CYP17A1, disrupting the early steps of glucocorticoid biosynthesis.

4. **Other Regulatory Mechanisms:**
- **Transcriptional regulation:** Several transcription factors, including nuclear receptors and other DNA-binding proteins, play crucial roles in regulating the expression of genes involved in glucocorticoid biosynthesis.
- **Post-translational modifications:** Various modifications, such as phosphorylation and ubiquitination, can affect the activity of enzymes involved in glucocorticoid biosynthesis.

In conclusion, negative regulation of glucocorticoid biosynthesis is a complex and tightly regulated process involving multiple levels of control. This regulation ensures that glucocorticoid production remains within a healthy range, preventing both excessive and insufficient production. Disruptions in this regulatory system can lead to various health issues, emphasizing the importance of maintaining its proper function.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Sodium/potassium-transporting ATPase subunit alpha-1 A sodium/potassium-transporting ATPase subunit alpha-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P05023]Homo sapiens (human)

Compounds (14)

CompoundDefinitionClassesRoles
lansoprazoleLansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.benzimidazoles;
pyridines;
sulfoxide
anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
omeprazole5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
pantoprazolepantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.

Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide
anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
digoxigenindigoxigenin : A hydroxy steroid that consists of 5beta-cardanolide having a double bond at the 20(22)-position as well as hydroxy groups at the 3beta-, 12beta- and 14beta-positions. It has been isolated from the plant species of the genus Digitalis.

Digoxigenin: 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide. A cardenolide which is the aglycon of digoxin. Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh.
12beta-hydroxy steroid;
14beta-hydroxy steroid;
3beta-hydroxy steroid;
3beta-sterol
hapten;
plant metabolite
digoxigenin-bis(digitoxoside)cardenolide glycoside
rostafuroxinrostafuroxin: structure in first source
ouabaincardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.

ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.

Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.
11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone
anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
digitoxindigitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.

Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
digoxindigoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.

Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
cardenolide glycoside;
steroid saponin
anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
digitoxigenindigitoxigenin : A 5beta-cardenolide that is 5beta-cardanolide with hydroxy substituents at the 3beta- and 14beta-positions and double bond unsaturation at C(20)-C(22).

Digitoxigenin: 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide. A cardenolide which is the aglycon of digitoxin. Synonyms: Cerberigenin; Echujetin; Evonogenin; Thevetigenin.
14beta-hydroxy steroid;
3beta-hydroxy steroid
phakellistatin 2phakellistatin 2: isolated from the marine sponge Phakellia carteri; structure in first source
digitoxigenin monodigitoxosidedigitoxigenin monodigitoxoside: RN given refers to (ribo-3beta,5beta)-isomer
evomonosideevomonoside : A cardenolide glycoside consisting of digitoxigenin having an alpha-L-rhamnosyl moiety attached at the O(3)-position.

evomonoside: a cytotoxic cardiac glycoside from Lepidium apetalum; RN refers to (3beta,5beta)-isomer
cardenolide glycoside
halisulfate 1halisulfate 1: an isocitrate lyase inhibitor sesterterpene sulfate from sponge, Hippospongia sp.; structure in first sourceorganic molecular entitymetabolite